Acquired Hemophilia Treatment Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3200/- USD | Published Date: October 28, 2020 |

The global acquired hemophilia treatment market size is projected to grow at a significant CAGR of over 6% market during the forecast period 2020-2027. According to the World Federation of Hemophilia, acquired hemophilia affects around two in every one million individuals worldwide, and across all ethnic groups. General clinical manifestations of acquired hemophilia are internal hemorrhage and extensive cutaneous purpura. Diagnosis of acquired hemophilia is based on detecting low factor VIII level linked with time-dependent inhibitor. Standard treatments of acquired hemophilia include administration of activated prothrombin, recombinant activated factor VI, and immunosuppressants with steroids. The monoclonal antibody, Rituximab is also used for autoantibody production suppression.

Market Insights:

Acquired hemophilia is a rare autoimmune disease with reported uncontrolled bleeding and occurs in patients with negative family and personal history of hemorrhages. Acquired hemophilia can cause life-threatening situations, where 50% of cases reportedly have underlying conditions. Major treatment strategies for managing acquired hemophilia include bleeding control and inhibitor elimination. Acquired hemophilia is an extremely rare form of blood disorder and affects around 2 of a million individuals globally. The disorder does not affect any particular ethnicity or rare and has a worldwide prevalence.

Market Segment Insights:

The types of traditional therapies used to treat acquired hemophilia are steroid treatment, cytotoxic therapy, and immunomodulatory therapy. The advanced treatment segmentation includes recombinant activated factor VII/NovoSeven RT, recombinant porcine factor VIII, activated prothrombin complex concentrate (aPCC)/FEIBA, and desmopressin (DDAVP). Bypassing agents such as FEIBA and NovoSeven are used as first-line treatment for controlling bleeding. International recommendations have stated that anti-hemorrhagic treatments should be promptly administered in patients with critical bleeding where acquired hemophilia is confirmed, irrespective of factor VIII activity and inhibitor titer. The use of bypassing agents or an increase of FVIII levels are the recommended and available treatment options. The choice between such alternatives is subject to the severity and site of bleeding and patient characteristics.

Global Acquired Hemophilia Treatment Market Segmentation:

By Product, 2018–2027 ($ Millon)

  • Traditional Therapy
  • Advanced Therapy
    • Desmopressin (DDAVP)
    • Recombinant Activated Factor VII/NovoSeven RT
    • Recombinant Porcine Factor VIII/Obizur
    • Activated Prothrombin Complex Concentrate (aPCC)/FEIBA

By Application, 2018–2027 ($ Millon)

By Geography, 2018-2027 ($ Millon)

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Regional Insights:

For the purpose of this study, the global acquired hemophilia treatment market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country-level markets that majorly determine the regional industry trends. North America was observed as the largest market for acquired hemophilia treatment in the base year 2015. North America dominated the market due to the aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. The Asia Pacific was observed as an attractive market due to emerging healthcare infrastructure, high disposable income, and transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.

Market Competition Assessment:

The major players currently operating in the global acquired hemophilia treatment market include Baxalta, Baxter, Bristol-Myers Squibb, Genentech, Novo Nordisk, Ferring BV, and Sanofi SA.

List of Key Companies:

  • Baxalta, Inc
  • Baxter Healthcare Corporation
  • Bristol-Myers Squibb
  • Genentech, Inc.
  • Novo Nordisk A/S
  • Ferring B.V.
  • Sanofi SA

To know more about the report, request a full report sample @ https://www.researchcorridor.com/request-sample/?id=144546

Key Questions Answered by Acquired Hemophilia Treatment Market Report

  • Global acquired hemophilia treatment market forecasts from 2020-2027
  • Regional acquired hemophilia treatment market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
  • Country level forecasts from 2020-2027 covering 15 major countries from aforementioned regions
  • Acquired Hemophilia Treatment submarket forecasts from 2020-2027 covering submarket 1, submarket 2 submarket 3
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to acquired hemophilia treatment market
  • Analysis of the key factors driving and restraining the growth of the global, regional and country level acquired hemophilia treatment markets from 2020-2027
  • Competitive Landscape and market positioning of top 10 players operating in the acquired hemophilia treatment market

Table of Content:


Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Acquired Hemophilia Treatment Market Portraiture
2.2 Acquired Hemophilia Treatment Market, by Therapeutic Type, 2019 ($ Million)
2.3 Acquired Hemophilia Treatment Market, by Application, 2019 ($ Million)
2.4 Acquired Hemophilia Treatment Market, by Geography, 2019 (Value %)
Chapter 3 Global Acquired Hemophilia Treatment Market Analysis
3.1 Global Acquired Hemophilia Treatment Market Overview
3.2 Prevalence of Acquired Hemophilia
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rise in Geriatric Population
3.3.1.2 Growing Demand for Prophylaxis Strategies
3.3.2 Challenges
3.3.2.1 Availability and Accessibility Constraints
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis: Global Acquired Hemophilia Treatment Market, 2015 (Value %)
Chapter 4 Global Acquired Hemophilia Treatment Market Analysis, By Type of Therapeutics, 2018-2027 ($ Million)
4.1 Preface
4.2 Traditional Therapy
4.3 Advanced Therapy
4.3.1 Desmopressin (DDAVP)
4.3.2 Recombinant Activated Factor VII/NovoSeven RT
4.3.3 Recombinant Porcine Factor VIII/Obizur
4.3.4 Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Chapter 5 Global Acquired Hemophilia Treatment Market, By Application, 2018-2027 ($ Million)
5.1 Preface
5.1 Pharmaceuticals
5.2 Food and Beverages
5.3 Feed Additives
5.4 Cosmetics
5.5 Others
Chapter 6 Global Acquired Hemophilia Treatment Market, By Geography, 2018-2027 ($ Million)
6.1 Preface
6.1 North America (U.S. & Canada)
6.2 Europe (U.K., Germany & Rest of Europe)
6.3 Asia Pacific (China, Japan, Singapore, South Korea and Rest of APAC)
6.4 Latin America (Mexico, Brazil and Rest of LATAM)
6.5 Middle East and Africa
Chapter 7 Company Profiles
7.1 Baxalta, Inc
7.2 Baxter Healthcare Corporation
7.3 Bristol-Myers Squibb
7.4 Genentech, Inc.
7.5 Novo Nordisk A/S
7.6 Ferring B.V.
7.7 Sanofi SA
Fill the given form to inquiry before buying for Acquired Hemophilia Treatment Market Report

Your Designtaion (required):


(Reports will be updated due to COVID-19 impacts on the market)

Request Report Sample
Inquiry Before Buying
Select License Type
$3200/- Single User License
$4800/- Multi User License
$6400/- Corporate License

Why To Choose Us:
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client base has an annual subscription membership
  • 24x7 availability we are always there when you need us
  • 100,000+ data points in our comprehensive database
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report
For Any Assitance
Call Us: +919893685690
Contact Person: Mr. Vijendra Singh
Contact Email: sales@researchcorridor.com